Combination indices for synergy experiments
| Cell lines . | CI at IC25 . | CI at IC50 . | CI at IC75 . | CI at IC90 . |
|---|---|---|---|---|
| K562 | 0.89 | 1.02 | 1.03 | 1.22 |
| KU812F | 0.95 | 1.00 | 0.99 | 0.90 |
| 32D.p210 | 0.90 | 0.88 | 1.01 | 1.23 |
| F317L-Ba/F3 | ND* | 0.50 | 0.49 | 0.52 |
| M351T-Ba/F3 | ND* | 0.64 | 0.91 | 0.94 |
| F486S-Ba/F3 | 1.03 | 1.15 | 1.14 | 1.28 |
| E255K-Ba/F3 | 0.74 | 0.78 | 0.88 | 0.90 |
| Cell lines . | CI at IC25 . | CI at IC50 . | CI at IC75 . | CI at IC90 . |
|---|---|---|---|---|
| K562 | 0.89 | 1.02 | 1.03 | 1.22 |
| KU812F | 0.95 | 1.00 | 0.99 | 0.90 |
| 32D.p210 | 0.90 | 0.88 | 1.01 | 1.23 |
| F317L-Ba/F3 | ND* | 0.50 | 0.49 | 0.52 |
| M351T-Ba/F3 | ND* | 0.64 | 0.91 | 0.94 |
| F486S-Ba/F3 | 1.03 | 1.15 | 1.14 | 1.28 |
| E255K-Ba/F3 | 0.74 | 0.78 | 0.88 | 0.90 |
Combination indices calculated for dose-response curves shown in Figures 1 and 2. These data are representative of 2 independent studies.
Missing IC25 values could not be calculated since the percentage of inhibition started at around 30% for imatinib alone and around 60% or 30% for the drug combination.